Attovia prices at $17 and starts Nasdaq trading today; no retail IPO path verified (2026)

August 5, 2026 is a regular NYSE trading day. The main US IPO event is no longer a filing: Attovia has priced, with shares expected to start trading today. The retail catch is unchanged: a public IPO allocation path through a mainstream broker is still not verified. 1

Today's spotlight: Attovia Therapeutics (ATTO)

Status: Priced at $17 per share. Attovia is offering 17 million shares for expected gross proceeds of $289 million. The issuer expects Nasdaq trading on August 5 and the offering to close on August 6, subject to customary conditions. Underwriters also have a 30-day option for 2.55 million more shares. 2

Business in one sentence: Attovia is a Phase 1 biotech developing biologic treatments for immune-mediated diseases, including chronic itching, atopic dermatitis and inflammatory bowel disease, through its ATTOBODY platform. 3

Why retail investors care: The deal expanded from the earlier 12.5 million-share plan to 17 million shares and priced at the top of the old $15-$17 range. Reuters described that combination as a demand signal and put the implied valuation at about $731.5 million. The bigger financing gives Attovia more capital for development, but it does not turn an early clinical program into an approved product. 4

Risk to monitor: Attovia has no products on the market and no product revenue. Its lead program is still in Phase 1. A failed or delayed move toward the next clinical stage would weaken the story; the company profile says its second candidate is only planned for a Phase 1 trial in the first half of 2027. 3

Minimum buy-in and broker access: No public IPO allocation notice was verified through Robinhood, Fidelity, Schwab, E*TRADE or Webull in the sources checked for this brief. That leaves the IPO minimum buy-in and subscription deadline unconfirmed. If ATTO appears in a brokerage app today, that is ordinary market trading after listing, not proof that the $17 IPO was available to that account.

Actionable now

No US IPO allocation met all four checks for this edition: public offer terms, a live deadline, a minimum buy-in and a verified path through a mainstream retail broker. The public calendars show deals and expected trading dates, but those entries do not establish retail subscription access. 5 6

Ticker	Price range	Minimum buy-in	Deadline	Verified brokers	Status
None verified	-	Not disclosed	No public allocation window found	None publicly verified	Watch only

ATTO, BRVE and VOGX are listing-watch names here, not subscription offers.

Market pulse

Attovia cleared the top of its old range. The company increased the proposed share count from 12.5 million to 17 million and priced at $17. That is a stronger execution signal than an unchanged deal, but it is not an oversubscription multiple. 4
Braveheart has a disclosed institutional signal. Fidelity Management & Research indicated interest in buying up to $75 million of BRVE shares at the IPO price. The proposed deal is 18.8 million shares at $15-$17, with expected trading August 6. Interest is not the same as a completed purchase or a retail allocation. 7 8
This week's calendar is heavily biotech-weighted. Renaissance lists five biotech or therapeutics deals among six current-week US IPOs, including BRVE at an estimated $300 million, ATTO at $289 million and LTGO at $272 million. That shows supply returning to healthcare; it does not prove that demand will be strong for every deal. 5

HK desk

No open Hong Kong public subscription was verified today. NASN TECH (2261) closed applications at noon on August 4. ET Net lists an offer range of HK$10.42-$11.18 and a 100-share board lot, putting the face-value minimum at HK$1,042-$1,118 before fees. August 5 is the price-determination date; results are due by August 6 and trading is scheduled for August 7. 9

ET Net's August 5 new-listings memo shows NASN TECH as the next Hong Kong debut and does not show another active public offer. The item to watch now is the final offer price and allotment result, not a new application. 10

On the radar: August 5-19

Public calendars currently disclose named US deals through August 12. They do not disclose separate pricing dates, and no additional Aug. 13-19 deal with a confirmed timetable appeared in the reviewed public pages.

Deal	Pricing date	Expected listing	Terms	Why watch
Braveheart Bio (BRVE)	Not disclosed	Aug. 6	18.8M shares at $15-$17; est. $300M	Oral BHB-1893 is being developed for hypertrophic cardiomyopathy, with global Phase 3 plans. 8
Vogenx (VOGX)	Not disclosed	Aug. 6	6.3M shares at $11-$13; est. $75M	Its lead drug, mizagliflozin, is in a Phase 2B program for post-bariatric hypoglycemia; the company has no product revenue. 11
BlossomHill Therapeutics (BLSM)	Not disclosed	Aug. 7	7.8M shares at $15-$17; est. $125M	Its lead program is in a Phase 1/2 trial for EGFR-mutant non-small cell lung cancer, with an FDA meeting planned for Q4 2026. 12
Latigo Biotherapeutics (LTGO)	Not disclosed	Aug. 7	16.0M shares at $16-$18; est. $272M	The company says it is ready for Phase 3 with non-opioid oral pain therapies. 13
Londian Wason New Energy Tech (FOIL)	Not disclosed	Aug. 12	3.6M ADS at $20-$22; est. $75M	The NYSE candidate makes copper foil used in lithium-ion batteries and counts CATL, BYD, LG Energy Solution, Samsung SDI and Panasonic among its customers. 14